KAYTUS
14.5.2024 09:01:37 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, has unveiled its latest upgrade, the K24V2 multi-node server, at ISC High Performance 2024. This server supports four dual-socket nodes within a compact 2U form factor, featuring a total of eight cutting-edge Intel/AMD processors. The K24V2 incorporates advanced cooling technologies optimized for extreme computing density, offering both cold plate liquid cooling and air cooling configurations. Notably, the liquid-cooling K24V2 cools components that account for more than 80% of the total power consumption, while the air-cooled variant supports CPU cooling with a TDP of up to 400W. With its emphasis on high performance, energy efficiency, and exceptional reliability, the K24V2 is tailored for demanding tasks such as modeling, simulation, and other performance-intensive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513994533/en/
K24V2 Multi-Node Server (Photo: Business Wire)
Achieving Four Times Computing Density and Higher Performance
The K24V2 server enables support for four dual-socket nodes within a 2U form factor, allowing for independent operations between nodes. Each node is compatible with two 5th Gen Intel® Xeon® processors or the latest 4th Gen AMD EPYC™ processors. It supports memory configurations up to 5600MT/s, and each node can accommodate various networking extensions such as InfiniBand, Omni-Path Architecture, and RoCE, meeting the networking requirements for HPC clusters.
Leading Cooling Solutions for Enhanced Performance and Efficiency
The liquid-cooled configuration of the K24V2 incorporates an integrated cold plate design that covers key components including the CPU, memory, and VR (Voltage Regulator). Components accounting for more than 80% of total power consumption are liquid cooled, offering efficient cooling while balancing investment control and power usage for heat dissipation. The cold plate supports various liquid-cooling connectors like SCG 03 and DAG 03, ensuring compatibility with different liquid-cooling cabinets used in data centers. The K24V2 is capable of supporting high-temperature inlet cooling liquids of up to 45°C, with the primary loop capable of drawing intake from a natural draft cooling tower. Furthermore, engineered to operate efficiently at an industry-leading ambient temperature of 45°C, this system significantly reduces energy consumption in data center operations.
The air-cooled version of the K24V2 maximizes heat dissipation performance through a high air intake design and a customized heat sink. This variant supports high-density deployments with CPUs of up to 400W TDP, delivering ultra-high performance and dense computing power tailored for air-cooled data centers.
Ensuring Security and Reliability, Streamlining Operations and Maintenance
Aside from delivering industry-leading performance per watt, the K24V2 is highly secure and reliable. The four nodes share titanium power supply units (PSUs), and the entire system supports N+N or 3+1 redundancy configurations. The liquid-cooled version features an integrated cold plate design and undergoes rigorous inspection processes before leaving the factory, including a nitrogen pressure test to effectively prevent leaks. Notably, the liquid-cooled version can identify leaking nodes in real-time, automatically cutting off node power to ensure the safety of equipment and data assets.
The K24V2 enhances user experience by offering convenient operation and maintenance features. The four nodes support hot-swappable maintenance and feature a "button"-style node switching on the front panel. This simplifies the connection of maintenance equipment for unified operations and maintenance, reduces work in the backend hot air duct, and improves overall user-friendliness.
To learn more about the new KAYTUS K24V2 Multi-Node Server, please visit our website.
About KAYTUS
KAYTUS is a prominent provider of IT infrastructure solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513994533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom